Log in
NASDAQ:IRMD

IRadimed Stock Forecast, Price & News

$23.92
-0.15 (-0.62 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$23.59
Now: $23.92
$24.30
50-Day Range
$21.11
MA: $22.66
$24.67
52-Week Range
$14.41
Now: $23.92
$28.43
Volume10,975 shs
Average Volume45,404 shs
Market Capitalization$293.50 million
P/E Ratio74.75
Dividend YieldN/A
Beta1.23
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Read More
IRadimed logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022
Employees114

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$38.52 million
Cash Flow$1.00 per share
Book Value$4.83 per share

Profitability

Net Income$9.63 million

Miscellaneous

Market Cap$293.50 million
Next Earnings Date2/4/2021 (Estimated)
OptionableNot Optionable
$23.92
-0.15 (-0.62 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IRadimed (NASDAQ:IRMD) Frequently Asked Questions

How has IRadimed's stock been impacted by COVID-19 (Coronavirus)?

IRadimed's stock was trading at $22.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IRMD stock has increased by 6.3% and is now trading at $23.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of IRadimed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IRadimed
.

What stocks does MarketBeat like better than IRadimed?

Wall Street analysts have given IRadimed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IRadimed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IRadimed's next earnings date?

IRadimed is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for IRadimed
.

How were IRadimed's earnings last quarter?

IRadimed Co. (NASDAQ:IRMD) posted its earnings results on Wednesday, November, 4th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. IRadimed had a return on equity of 6.93% and a net margin of 11.67%.
View IRadimed's earnings history
.

What price target have analysts set for IRMD?

1 equities research analysts have issued 12-month price targets for IRadimed's shares. Their forecasts range from $26.00 to $26.00. On average, they anticipate IRadimed's stock price to reach $26.00 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for IRadimed
.

Are investors shorting IRadimed?

IRadimed saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 165,700 shares, a decrease of 32.9% from the September 30th total of 247,100 shares. Based on an average trading volume of 40,600 shares, the short-interest ratio is currently 4.1 days. Currently, 2.7% of the company's stock are sold short.
View IRadimed's Short Interest
.

Who are some of IRadimed's key competitors?

What other stocks do shareholders of IRadimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

Who are IRadimed's key executives?

IRadimed's management team includes the following people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 67, Pay $488.45k)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 50, Pay $337.77k)
  • Ms. Mary Beth Smith, VP of Sales
  • Mr. Matt Garner, Controller

What is IRadimed's stock symbol?

IRadimed trades on the NASDAQ under the ticker symbol "IRMD."

Who are IRadimed's major shareholders?

IRadimed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nine Ten Capital Management LLC (4.48%), BlackRock Inc. (3.40%), RK Capital Management LLC (1.77%), Foundry Partners LLC (0.72%), State Street Corp (0.71%) and Assenagon Asset Management S.A. (0.51%). Company insiders that own IRadimed stock include Anthony Vuoto, Brent Johnson, Louis S Waldman, Monty K Allen and Steven M Nardi.
View institutional ownership trends for IRadimed
.

Which institutional investors are selling IRadimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Acadian Asset Management LLC, RK Capital Management LLC, Morgan Stanley, WINTON GROUP Ltd, AQR Capital Management LLC, BlackRock Inc., and Wells Fargo & Company MN. Company insiders that have sold IRadimed company stock in the last year include Brent Johnson, Louis S Waldman, and Monty K Allen.
View insider buying and selling activity for IRadimed
.

Which institutional investors are buying IRadimed stock?

IRMD stock was purchased by a variety of institutional investors in the last quarter, including Nine Ten Capital Management LLC, Assenagon Asset Management S.A., Foundry Partners LLC, State Street Corp, California Public Employees Retirement System, Captrust Financial Advisors, Nisa Investment Advisors LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for IRadimed
.

How do I buy shares of IRadimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IRadimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $23.92.

How big of a company is IRadimed?

IRadimed has a market capitalization of $293.50 million and generates $38.52 million in revenue each year. The medical equipment provider earns $9.63 million in net income (profit) each year or $0.78 on an earnings per share basis. IRadimed employs 114 workers across the globe.

What is IRadimed's official website?

The official website for IRadimed is www.iradimed.com.

How can I contact IRadimed?

IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.